Summit invests in cancer biomarker specialist
This article was originally published in Clinica
Boston, Massachusetts-based investment firm Summit Partners has taken an equity stake in ApoCell, a contract research organisation (CRO) specialising in cancer-related molecular diagnostics. The investment, of an undisclosed amount, will be used to support ApoCell’s ongoing development of its technology platforms. Spun out of the University of Texas in 2005, the Houston-based CRO specialises in protein biomarker detection and analysis of rare cells in blood and tissue specimens from clinical trial subjects. It also develops and manufactures custom biomarker analysis and site collection kits, and companion diagnostic testing kits.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.